New York Senate Bill S10232

New York 2025-2026 Regular Session

• Introduced: 5/7/26
• Refer: 5/7/26

Caption

Relates to not requiring a prior authorization determination for certain categories of cancer treatments based on National Comprehensive Cancer Network Guidelines.

Summary

S10232 would prohibit insurers, health care plans, and Medicaid managed care providers in New York from requiring prior authorization for certain cancer treatments that fall within Category 1 or Category 2A of the National Comprehensive Cancer Network (NCCN) evidence and consensus guidelines. The bill applies the same rule across the insurance law, public health law, and social services law, covering commercial insurers, health plans, and managed care providers. Providers could still be asked to certify that the treatment meets NCCN guidelines, and payers would retain the ability to deny claims later if the services are found not to be medically necessary. The measure is designed to reduce administrative delay for oncology patients receiving widely accepted cancer therapies. By removing prior authorization for treatments already supported by NCCN guidelines, the bill seeks to speed access to care while preserving payer oversight through post-service medical necessity review. The bill would take effect 180 days after becoming law, and the Medicaid managed care amendment would expire if the underlying social services law provision expires or is repealed.

Impact

The bill would amend three separate bodies of New York law: Insurance Law sections 3217-b and 4325, Public Health Law section 4406-c, and Social Services Law section 364-j. Its practical effect would be to bar prior authorization requirements for specified NCCN Category 1 and 2A cancer treatments across most private insurance and managed care arrangements, while allowing certification and later claim review for medical necessity. This would reduce utilization-management barriers for oncology care and could increase timely access to guideline-supported cancer therapies for insured patients and Medicaid managed care enrollees.

Sentiment

The available record shows no committee transcript or vote history, so there is no documented debate or recorded vote sentiment to assess. Based on the bill text alone, the proposal appears patient-access oriented and narrowly targeted, with an emphasis on reducing administrative burden for cancer treatment while preserving insurer safeguards. The absence of recorded opposition or amendments in the provided materials suggests the bill had not yet generated a formal public legislative record at the time of introduction.

Contention

The main policy tension in the bill is between faster access to cancer treatment and payer control over utilization and costs. Supporters would likely favor eliminating prior authorization for NCCN-supported therapies to avoid delays in oncology care, while insurers and managed care plans may be concerned about reduced upfront review and potential cost increases. The bill addresses that concern by allowing certification of guideline compliance and preserving the right to deny claims later if treatment is not medically necessary, but the balance between access and oversight remains the central point of contention.